{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:53:00Z","timestamp":1792687980565,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T00:00:00Z","timestamp":1471478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T00:00:00Z","timestamp":1471478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study assessed the <jats:italic>in vitro<\/jats:italic> antibacterial activity of combinations of amikacin and doxycycline or tigecycline against multidrug-resistant <jats:italic>E. coli<\/jats:italic> isolates. Twenty-four different pulsotypes, including 10 extended-spectrum \u03b2-lactamase (ESBL)-, 10 carbapenem-resistant, 2 New Delhi Metallo-beta-lactamase (NDM)- and 2 Klebsiella pneumoniae carbapenemase (KPC)-<jats:italic>E. coli<\/jats:italic> isolates were collected. All 24 isolates were susceptible to amikacin and tigecycline. Only 30% of ESBL and 50% of carbapenem-resistant <jats:italic>E. coli<\/jats:italic> were susceptible to doxycycline. Both of the NDM-<jats:italic>E. coli<\/jats:italic> had a MIC of 64\u2009\u03bcg\/ml. The checkerboard method showed that for the ESBL- and carbapenem-resistant <jats:italic>E. coli<\/jats:italic>, the synergistic effects of amikacin\/doxycycline were 80% and 90%, respectively. For the two KPC- and two NDM-<jats:italic>E. coli<\/jats:italic>, the FIC index of amikacin\/doxycycline were 0.5\/0.375 and 0.5\/0.281, respectively. For the ESBL- and carbapenem-resistant <jats:italic>E. coli<\/jats:italic> isolates, the combinations of amikacin and doxycycline exhibited synergistic activities against 80%, and 80% and 10% vs 60%, and 80% and 10% of the isolates at concentrations of 1x, 1\/2x and 1\/4xMIC, respectively. The synergistic effect seems to be similar for doxycycline and tigecycline based combinations with amikacin. In conclusion, the antibacterial activity of doxycycline can be enhanced by the addition of amikacin and is observed against most multidrug-resistant <jats:italic>E. coli<\/jats:italic> isolates.<\/jats:p>","DOI":"10.1038\/srep31964","type":"journal-article","created":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T09:42:49Z","timestamp":1471513369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["The role of doxycycline in the therapy of multidrug-resistant E. coli \u2013 an in vitro study"],"prefix":"10.1038","volume":"6","author":[{"given":"Chih-Cheng","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Ching","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Jen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,18]]},"reference":[{"key":"BFsrep31964_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4065\/mcp.2010.0674","volume":"86","author":"SS Kanj","year":"2011","unstructured":"Kanj, S. S. & Kanafani, Z. A. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin. Proc. 86, 250\u2013259, doi:10.4065\/mcp.2010.0674 (2011).","journal-title":"Mayo Clin. Proc."},{"key":"BFsrep31964_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2217\/fmb.11.49","volume":"6","author":"ME Falagas","year":"2011","unstructured":"Falagas, M. E., Karageorgopoulos, D. E. & Nordmann, P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 6, 653\u2013666, doi:10.2217\/fmb.11.49 (2011).","journal-title":"Future Microbiol."},{"key":"BFsrep31964_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1055\/s-0035-1544208","volume":"36","author":"Y Doi","year":"2015","unstructured":"Doi, Y. & Paterson, D. L. Carbapenemase-producing Enterobacteriaceae. Semin. Respir. Crit. Care Med. 36, 74\u201384, doi:10.1055\/s-0035-1544208 (2015).","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"BFsrep31964_CR4","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1111\/j.1469-0691.2011.03514.x","volume":"17","author":"O Zarkotou","year":"2011","unstructured":"Zarkotou, O. et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin. Microbiol. Infect 17, 1798\u20131803, doi:10.1111\/j.1469-0691.2011.03514.x (2011).","journal-title":"Clin. Microbiol. Infect"},{"key":"BFsrep31964_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1128\/aac.06268-11","volume":"56","author":"ZA Qureshi","year":"2012","unstructured":"Qureshi, Z. A. et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56, 2108\u20132113, doi:10.1128\/aac.06268-11 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep31964_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/cid\/cis588","volume":"55","author":"M Tumbarello","year":"2012","unstructured":"Tumbarello, M. et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin. Infect Dis. 55, 943\u2013950, doi:10.1093\/cid\/cis588 (2012).","journal-title":"Clin. Infect Dis."},{"key":"BFsrep31964_CR7","unstructured":"Tang, H. J. et al. Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin. J. Microbiol. Immunol. Infect. (in press) (2016)."},{"key":"BFsrep31964_CR8","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/1469-0691.12697","volume":"20","author":"LS Tzouvelekis","year":"2014","unstructured":"Tzouvelekis, L. S., Markogiannakis, A., Piperaki, E., Souli, M. & Daikos, G. L. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin. Microbiol. Infect 20, 862\u2013872, doi:10.1111\/1469-0691.12697 (2014).","journal-title":"Clin. Microbiol. Infect"},{"key":"BFsrep31964_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4103\/2279-042x.162360","volume":"4","author":"M Izadpanah","year":"2015","unstructured":"Izadpanah, M. & Khalili, H. Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature review. J. Res. Pharm. Pract. 4, 105\u2013114, doi:10.4103\/2279-042x.162360 (2015).","journal-title":"J. Res. Pharm. Pract."},{"key":"BFsrep31964_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/cmr.05041-11","volume":"25","author":"PD Tamma","year":"2012","unstructured":"Tamma, P. D., Cosgrove, S. E. & Maragakis, L. L. Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microbiol. Rev. 25, 450\u2013470, doi:10.1128\/cmr.05041-11 (2012).","journal-title":"Clin. Microbiol. Rev."},{"key":"BFsrep31964_CR11","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1093\/cid\/cir475","volume":"53","author":"MH Kollef","year":"2011","unstructured":"Kollef, M. H., Golan, Y., Micek, S. T., Shorr, A. F. & Restrepo, M. I. Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections\u2013proceedings and data from the Gram-Negative Resistance Summit. Clin. Infect. Dis. 53 Suppl 2, S33\u201355; quiz S56\u201338, doi:10.1093\/cid\/cir475 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep31964_CR12","unstructured":"National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 9th informational supplement. M100-S24. National Committee for Clinical Laboratory Standards, Wayne, Pa. (2014)."},{"key":"BFsrep31964_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1186\/1471-2334-13-599","volume":"13","author":"L Ma","year":"2013","unstructured":"Ma, L. et al. Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: first identification of KPC-2 or NDM-1-producing E. coli in Taiwan. BMC infect. Dis. 13, 599, doi:10.1186\/1471-2334-13-599 (2013).","journal-title":"BMC infect. Dis."},{"key":"BFsrep31964_CR14","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing. Document M100-S24. Wayne, PA CLSI. (2014)."},{"key":"BFsrep31964_CR15","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1128\/jcm.02351-06","volume":"45","author":"SD Brown","year":"2007","unstructured":"Brown, S. D. & Traczewski, M. M. Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J. Clin. Microbiol. 45, 2173\u20132179, doi:10.1128\/jcm.02351-06 (2007).","journal-title":"J. Clin. Microbiol."},{"key":"BFsrep31964_CR16","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Eighth Edition Approved Standard M07-A9. CLSI, Wayne, PA, USA. (2009)."},{"key":"BFsrep31964_CR17","unstructured":"National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Wayne, PA NCCLS. (1999)."},{"key":"BFsrep31964_CR18","unstructured":"Eliopoulos G. M. & a. R. C. M. Jr. In V. Lorian. Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md. Antimicrobial combinations. 330\u2013396 (1996)."},{"key":"BFsrep31964_CR19","unstructured":"JA, M. Synergy testing: broth microdilution checkerboard and broth macrodilution methods, p. 5.18.1\u20135.18.23. In H. D. Eisenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, D.C. (1992)."},{"key":"BFsrep31964_CR20","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1128\/AAC.40.8.1914","volume":"40","author":"RL White","year":"1996","unstructured":"White, R. L., Burgess, D. S., Manduru, M. & Bosso, J. A. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob. Agents Chemother. 40, 1914\u20131918 (1996).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep31964_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1128\/CMR.00001-07","volume":"20","author":"AM Queenan","year":"2007","unstructured":"Queenan, A. M. & Bush, K. Carbapenemases: the versatile beta-lactamases. Clin. Microbiol. Rev. 20, 440\u2013458 (2007).","journal-title":"Clin. Microbiol. Rev."},{"key":"BFsrep31964_CR22","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1128\/AAC.48.4.1249-1255.2004","volume":"48","author":"C Eckert","year":"2004","unstructured":"Eckert, C. et al. Dissemination of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob. Agents Chemother. 48, 1249\u20131255 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep31964_CR23","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1128\/aac.01247-10","volume":"55","author":"L Poirel","year":"2011","unstructured":"Poirel, L., Revathi, G., Bernabeu, S. & Nordmann, P. Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. Antimicrob. Agents Chemother. 55, 934\u2013936, doi:10.1128\/aac.01247-10 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep31964_CR24","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1128\/JCM.44.5.1776-1781.2006","volume":"44","author":"K Ejrnaes","year":"2006","unstructured":"Ejrnaes, K. et al. Pulsed-field gel electrophoresis typing of Escherichia coli strains from samples collected before and after pivmecillinam or placebo treatment of uncomplicated community-acquired urinary tract infection in women. J. Clin. Microbiol. 44, 1776\u20131781, (2006).","journal-title":"J. Clin. Microbiol."},{"key":"BFsrep31964_CR25","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1128\/jcm.33.9.2233-2239.1995","volume":"33","author":"FC Tenover","year":"1995","unstructured":"Tenover, F. C. et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol 33, 2233\u20132239 (1995).","journal-title":"J. Clin. Microbiol"},{"key":"BFsrep31964_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/PL00002075","volume":"95","author":"T Ziegler","year":"2000","unstructured":"Ziegler, T., Winkler, C., Wege, K. & Schmechel, H. Doxycycline\u2013the forgotten antibiotic. Med. Klin. (Munich). 95, 629\u2013631 (2000).","journal-title":"Med. Klin. (Munich)."},{"key":"BFsrep31964_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/00003495-200464010-00005","volume":"64","author":"GG Zhanel","year":"2004","unstructured":"Zhanel, G. G. et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64, 63\u201388 (2004).","journal-title":"Drugs"},{"key":"BFsrep31964_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ijantimicag.2014.12.031","volume":"45","author":"ME Falagas","year":"2015","unstructured":"Falagas, M. E., Vardakas, K. Z., Kapaskelis, A., Triarides, N. A. & Roussos, N. S. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int. J. Antimicrob. Agents. 45, 455\u2013460, doi:10.1016\/j.ijantimicag.2014.12.031 (2015).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"BFsrep31964_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ijantimicag.2005.10.012","volume":"27","author":"F Timurkaynak","year":"2006","unstructured":"Timurkaynak, F. et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents. 27, 224\u2013228, doi: 10.1016\/j.ijantimicag.2005.10.012 (2006).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"BFsrep31964_CR30","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1345\/aph.1P217","volume":"44","author":"GC Wood","year":"2010","unstructured":"Wood, G. C., Underwood, E. L., Croce, M. A., Swanson, J. M. & Fabian, T. C. Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin. Ann. Pharmacother. 44, 1665\u20131668, doi:10.1345\/aph.1P217 (2010).","journal-title":"Ann. Pharmacother."},{"key":"BFsrep31964_CR31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/jac\/dkq108","volume":"65","author":"EB Hirsch","year":"2010","unstructured":"Hirsch, E. B. & Tam, V. H. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 65, 1119\u20131125, doi:10.1093\/jac\/dkq108 (2010).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep31964_CR32","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.clinthera.2006.08.011","volume":"28","author":"TL Doan","year":"2006","unstructured":"Doan, T. L., Fung, H. B., Mehta, D. & Riska, P. F. Tigecycline: a glycylcycline antimicrobial agent. Clin. Ther. 28, 1079\u20131106, doi:10.1016\/j.clinthera.2006.08.011 (2006).","journal-title":"Clin. Ther."},{"key":"BFsrep31964_CR33","doi-asserted-by":"crossref","unstructured":"Xu, A. et al. National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013. Clin. Microbiol Infect. doi:10.1016\/j.cmi.2015.09.015 (2016).","DOI":"10.1016\/j.cmi.2015.09.015"},{"key":"BFsrep31964_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000375440","volume":"60","author":"S Ozkok","year":"2014","unstructured":"Ozkok, S. et al. In vitro susceptibility of tigecycline against multidrug-resistant gram-negative strains: Etest versus agar dilution. Chemother. 60, 151\u2013156, doi:10.1159\/000375440 (2014).","journal-title":"Chemother."},{"key":"BFsrep31964_CR35","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1128\/aac.06053-11","volume":"56","author":"YH Chen","year":"2012","unstructured":"Chen, Y. H. et al. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline in vitro Surveillance in Taiwan study, 2006 to 2010. Antimicrob. Agents Chemother. 56, 1452\u20131457, doi:10.1128\/aac.06053-11 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep31964_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.diagmicrobio.2005.05.006","volume":"52","author":"AK Meagher","year":"2005","unstructured":"Meagher, A. K., Ambrose, P. G., Grasela, T. H. & Ellis-Grosse, E. J. Pharmacokinetic\/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn. Microbiol. Infect. Dis. 52, 165\u2013171, doi:10.1016\/j.diagmicrobio.2005.05.006 (2005).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"BFsrep31964_CR37","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s10096-015-2379-9","volume":"34","author":"G Meletis","year":"2015","unstructured":"Meletis, G., Chatzidimitriou, D. & Malisiovas, N. Double- and multi-carbapenemase-producers: the excessively armored bacilli of the current decade. Eur. J. Clin. Microbiol. Infect. Dis. 34, 1487\u20131493, doi:10.1007\/s10096-015-2379-9 (2015).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"BFsrep31964_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1089\/mdr.2014.0171","volume":"21","author":"PS Pereira","year":"2015","unstructured":"Pereira, P. S. et al. Coproduction of NDM-1 and KPC-2 in Enterobacter hormaechei from Brazil. Microbial. Drug Resist. 21, 234\u2013236, doi:10.1089\/mdr.2014.0171 (2015).","journal-title":"Microbial. Drug Resist."},{"key":"BFsrep31964_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1590\/1414-431x20144154","volume":"48","author":"MG Quiles","year":"2015","unstructured":"Quiles, M. G. et al. Unusual association of NDM-1 with KPC-2 and armA among Brazilian Enterobacteriaceae isolates. Braz. J. Med. Biol. Res. 48, 174\u2013177, doi:10.1590\/1414-431x20144154 (2015).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"BFsrep31964_CR40","doi-asserted-by":"crossref","unstructured":"Sattar, H., Toleman, M., Nahid, F. & Zahra, R. Co-existence of bla and bla in clinical isolates of Klebsiella pneumoniae from Pakistan. J. Chemother. 1973947814y0000000223, doi:10.1179\/1973947814y.0000000223 (2014).","DOI":"10.1179\/1973947814Y.0000000223"},{"key":"BFsrep31964_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/jac\/dkr431","volume":"67","author":"K Kumarasamy","year":"2012","unstructured":"Kumarasamy, K. & Kalyanasundaram, A. Emergence of Klebsiella pneumoniae isolate co-producing NDM-1 with KPC-2 from India. J. Antimicrobial. Chemother. 67, 243\u2013244, doi:10.1093\/jac\/dkr431 (2012).","journal-title":"J. Antimicrobial. Chemother."},{"key":"BFsrep31964_CR42","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1128\/JCM.42.8.3831-3833.2004","volume":"42","author":"L Poirel","year":"2004","unstructured":"Poirel, L., Heritier, C., Spicq, C. & Nordmann P. In vivo acquistion of high-level resistance to imipenem in Escherichia coli . J. Clin. Microbiol. 42, 3831\u20133833 (2004).","journal-title":"J. Clin. Microbiol."},{"key":"BFsrep31964_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1186\/1471-2334-13-599","volume":"13","author":"L Ma","year":"2013","unstructured":"Ma, L. et al. Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: first identification of KPC-2 or NDM-1-producing E. coli in Taiwan. BMC Infect. Dis. 13, 599 (2013).","journal-title":"BMC Infect. Dis."},{"key":"BFsrep31964_CR44","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1179\/joc.2009.21.6.621","volume":"21","author":"JH Chia","year":"2009","unstructured":"Chia, J. H. et al. Emergence of carbapenem-resistant Escherichia coli in Taiwan: resistance due to combined CMY-2 production and porin deficiency. J. Chemother. 21, 621\u2013626 (2009).","journal-title":"J. Chemother."},{"key":"BFsrep31964_CR45","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1093\/jac\/dkv232","volume":"70","author":"J Feng","year":"2015","unstructured":"Feng, J. et al. Coexistence of a novel KPC-2-encoding MDR plasmid and an NDM-1-encoding pNDM-HN380-like plasmid in a clinical isolate of Citrobacter freundii. J. Antimicrobial. Chemother. 70, 2987\u20132991, doi:10.1093\/jac\/dkv232 (2015).","journal-title":"J. Antimicrobial. Chemother."},{"key":"BFsrep31964_CR46","doi-asserted-by":"crossref","unstructured":"Laishram, S. et al. Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiellapneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance. J. Chemother. 2015 Oct 2:1973947815Y0000000079. [Epub ahead of print].","DOI":"10.1179\/1973947815Y.0000000079"},{"key":"BFsrep31964_CR47","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1128\/AAC.02411-12","volume":"57","author":"JH Hong","year":"2013","unstructured":"Hong, J. H. et al. Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob. Agents Chemother. 57, 2147\u20132153 (2013).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep31964.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep31964","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep31964.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:30:43Z","timestamp":1672900243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep31964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,18]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,8,31]]}},"alternative-id":["BFsrep31964"],"URL":"https:\/\/doi.org\/10.1038\/srep31964","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,18]]},"assertion":[{"value":"21 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31964"}}